IPP Bureau
CRISIL positive on Krishna Institute of Medical Sciences
By IPP Bureau - August 25, 2021
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Carbogen Amcis AG signs co-investment agreement
By IPP Bureau - August 25, 2021
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Govt to offer incentives to support 75 start-ups in Tele-Medicine, AI and Digital Health
By IPP Bureau - August 25, 2021
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Pfizer to acquire Trillium Therapeutics
By IPP Bureau - August 24, 2021
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Infosys Foundation constructs OPD block at the Kidwai Memorial Institute of Oncology, Bangalore
By IPP Bureau - August 24, 2021
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
New data demonstrates efficacy of Viraleze anti-nasal spray for Covid-19
By IPP Bureau - August 24, 2021
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Xybion releases Pristima XD digital pathology
By IPP Bureau - August 24, 2021
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
Lupin launches Luforbec to treat asthma & COPD in UK
By IPP Bureau - August 24, 2021
It is the first branded generic alternative to Fostair 100/6 pMDI
Neuberg Diagnostics appoints MS Dhoni as brand ambassador
By IPP Bureau - August 24, 2021
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
13 hospitals across India complete first cycle of PRIME programme
By IPP Bureau - August 24, 2021
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
By IPP Bureau - August 24, 2021
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Mercer/Mettl facilitates integration of PMGDisha and CoWin
By IPP Bureau - August 24, 2021
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
U.S. FDA approval of KORSUVA injection
By IPP Bureau - August 24, 2021
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Roche and KeChow to commercialise Zelboraf
By IPP Bureau - August 23, 2021
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
Delfi liquid biopsy shows promise for reducing lung cancer deaths
By IPP Bureau - August 23, 2021
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
